National Institute for Tuberculosis and Lung Diseases, Poland   Report issue

Academic/Hospital Phase 4
Founded: Warsaw Poland (1951)

Organization Overview

First Clinical Trial
2015
NCT03444636
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

National Institute for Tuberculosis and Lung Diseases, Poland

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Diseases (Phase 4)

Lung Diseases, Interstitial (Phase 4)

Lung Neoplasms (Phase 4)

Neoplasms (Phase 4)

Pain, Postoperative (Phase 4)

Pneumonia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 6